摘要
目的:探讨治疗慢性心力衰竭不同方案的临床效果,并对其进行经济学分析。方法:148例慢性心力衰竭患者,以随机抽样法分为3组,第1组应用卡托普利及常规治疗,第2组应用卡托普利+厄贝沙坦氢氯噻嗪,第3组应用贝那普利+缬沙坦。观察心功能与心脏结构的变化,并进行经济学分析(直接药费成本)。结果:第1组日均直接药费为0.314元,第2组为4.129元,第3组为10.194元。结论:在应用血管紧张素转换酶抑制剂(ACEI)的基础上加用血管紧张素Ⅱ受体阻断剂(ARB)可以明显改善左心室射血分数、左心室舒张末期内径和左心室短轴缩短率及心脏比例。
OBJECTIVE ： To evaluate the clinical efficacy and pharmacoeconomics of three regimens for chronic heart failure. METHODS： A total of 148 patients with chronic heart failure were randomly assigned to receive captopril plus routine therapy （Group 1 ）, captopril combined with irbesartan hydrochlorothiazide （Group 2） or benazepril plus valsartan （Group 3）. The cardiac function and structure were followed and economic analyses（direct drug costs） were performed. RESULTS： The direct drug costs in Group 1, 2 and 3 were 0. 314 yuan, 4. 129 yuan and 10. 194 yuan, respectively. CONCLUSION： Addition of adrenergic receptor binder （ARB） to angiotensin-converting enzyme inhibitor （ACEI） significantly improved left ventricular ejection fraction, left ventricular end-diastolic diameter, left ventricular shortening fraction and ratio of heart.
出处
《中国医院用药评价与分析》
2012年第1期56-57,共2页
Evaluation and Analysis of Drug-use in Hospitals of China
